Russia's Chemrar plans development of orphan medicines with Genzyme
This article was originally published in Scrip
Executive Summary
Genzyme and Russia's centre for high technologies, Chemrar, have signed a memorandum of understanding and partnership for the development of biotechnological and synthetic drugs for orphan diseases. If realised, the execution of R&D, production and commercialisation under the project will be conducted at Chemrar's premises near Moscow.